Nov. 10 (Bloomberg) -- Genmab A/S, the Danish biotechnology company, was cut to “underperform” from “neutral” at Credit Suisse Group AG, which cited “reduced peak sales estimates” for its Arzerra leukemia treatment.

Last Updated: November 10, 2009 01:42 EST